Announcement PDF Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name of Entity: Radiopharm Theranostics Limited (ASX: RAD) ABN: 57 647 877 889 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director: Bruce Goodwin Date of Last Notice: 19 November 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or Indirect Interest Indirect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Sundial Management Pty Limited of which Mr Goodwin is a Director and Shareholder. Date of change 17 September 2026 No. of securities held prior to change Nil Class a. Fully Paid Ordinary Shares b. Listed Options Number acquired a. 2,777,778 Fully Paid Ordinary Shares b. 2,777,778 Listed Options, EXP 31 Jul 29, EX $0.018 Number disposed Nil Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation a. $25,000 ($0.009 per Share) b. Nil Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change Shares Options Indirect 2,777,778 2,777,778 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Acquisition of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September 2026. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Part 3 – Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name of Entity: Radiopharm Theranostics Limited (ASX: RAD) ABN: 57 647 877 889 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director: Ian Turner Date of Last Notice: 27 August 2026 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or Indirect Interest Direct and indirect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Superannuation fund Date of change 17 September 2026 No. of securities held prior to change Shares Options Direct 2,530,595 21,956,926 Indirect 7,454,697 70,422 Total 9,985,292 22,027,348 Class a. Fully Paid Ordinary Shares b. Listed Options Number acquired Direct a. 1,222,222 Fully Paid Ordinary Shares b. 1,222,222 Listed Options, EXP 31 Jul 29, EX $0.018 Indirect a. 1,555,556 Fully Paid Ordinary Shares b. 1,555,556 Listed Options, EXP 31 Jul 29, EX $0.018 Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Number disposed Nil Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation a. $25,000 ($0.009 per Share) b. Nil No. of securities held after change Shares Options Direct 3,752,817 23,179,148 Indirect 9,010,253 1,625,978 Total 12,763,070 24,805,126 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Acquisition of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September 2026. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Part 3 – Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name of Entity: Radiopharm Theranostics Limited (ASX: RAD) ABN: 57 647 877 889 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director: Paul Hopper Date of Last Notice: 27 August 2026 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or Indirect Interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. N/A Date of change 17 September 2026 No. of securities held prior to change Shares Options Direct 53,900,000 26,142,000 Indirect 93,821,428 9,017,518 Total 147,721,428 35,159,518 Class a. Fully Paid Ordinary Shares b. Listed Options Number acquired Indirect a. 2,777,778 Fully Paid Ordinary Shares b. 2,777,778 Listed Options, EXP 31 Jul 29, EX $0.018 Number disposed Nil Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation a. $25,000 ($0.009 per Share) b. Nil Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change Shares Options Direct 53,900,000 26,142,000 Indirect 96,599,206 11,795,296 Total 150,499,206 37,937,296 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Acquisition of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September 2026. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Part 3 – Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name of Entity: Radiopharm Theranostics Limited (ASX: RAD) ABN: 57 647 877 889 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director: Riccardo Canevari Date of Last Notice: 27 August 2026 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or Indirect Interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. N/A Date of change 17 September 2026 No. of securities held prior to change Shares Options Direct 20,029,986 183,412,299 Indirect 2,650,000 - Total 22,679,986 183,412,299 Class a. Fully Paid Ordinary Shares b. Listed Options Number acquired a. 3,888,889 Fully Paid Ordinary Shares b. 3,888,889 Listed Options, EXP 31 Jul 29, EX $0.018 Number disposed Nil Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation a. $35,000 ($0.009 per Share) b. Nil Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change Shares Options Direct 23,918,875 187,301,188 Indirect 2,650,000 - Total 26,568,875 187,301,188 Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Acquisition of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September 2026. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Part 3 – Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A